DVN
32
3
ROST
49
2
ZION
61
4
VFC
42
3
BAX
48
3
PBI
50
-3
NDAQ
71
-2
TSCO
52
3
CNX
42
-2
SYF
64
2
EIX
53
2
LYB
8
4
IFF
45
4
TXT
68
6
EQR
31
-5
RHI
27
2
STT
70
5
NWL
32
9
LNC
43
4
COP
37
3
DVN
32
3
ROST
49
2
ZION
61
4
VFC
42
3
BAX
48
3
PBI
50
-3
NDAQ
71
-2
TSCO
52
3
CNX
42
-2
SYF
64
2
EIX
53
2
LYB
8
4
IFF
45
4
TXT
68
6
EQR
31
-5
RHI
27
2
STT
70
5
NWL
32
9
LNC
43
4
COP
37
3
Financhill
Back

Aligos Therapeutics 10K Form

Sell
45

ALGS
Aligos Therapeutics

Last Price:
$6.24
Seasonality Move:
-16.73%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

10K form not available

Receive ALGS News And Ratings

See the #1 stock for the next 7 days that we like better than ALGS

ALGS Financial Statistics

Sales & Book Value

Annual Sales: $3.9M
Cash Flow: $-21M
Price / Cash Flow: 0
Annual Sales: $19.04
Price / Book: 0.31

Profitability

EPS (TTM): -17.51000
Net Income (TTM): $-53.3M
Gross Margin: --
Return on Equity: -100.65%
Return on Assets: -48.78%

Aligos Therapeutics Earnings Forecast

Key Aligos Therapeutics Financial Ratios

  • The Research & Development expenses have been 1,781.22% of Revenue.
  • The Net Earning history of ALGS is -3,326.01% of Total Revenues.
  • Per Share Earnings over the last 6 years have been positive in 4 years.

Aligos Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: ALGS
Website: aligos.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 7.56
Quick Ratio: 7.28

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

ALGS Technical Analysis vs Fundamental Analysis

Sell
45
Aligos Therapeutics (ALGS) is a Sell

Is Aligos Therapeutics a Buy or a Sell?